Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study
Table 2
Clinical events through 5 years.
At 1 year
From 1 to 5 years
ACS
SCAD
value
ACS
SCAD
value
All-cause death
35 (5.5%)
30 (2.4%)
<0.001
44 (9.1%)
105 (10.0%)
0.460
Cardiac death
25 (3.9%)
15 (1.2%)
<0.001
18 (3.7%)
32 (3.1%)
0.373
Myocardial infarction
15 (2.4%)
18 (1.5%)
0.132
16 (3.3%)
17 (1.8%)
0.008
Target vessel myocardial infarction
11 (1.8%)
9 (0.7%)
0.039
7 (1.4%)
10 (1.0%)
0.227
All-cause death or myocardial infarction
47 (7.4%)
47 (3.8%)
<0.001
56 (11.6%)
118 (11.4%)
0.706
Ischemia-driven TLR
18 (3.0%)
33 (2.7%)
0.682
13 (2.7%)
31 (2.9%)
0.864
Target lesion failure
47 (7.5%)
53 (4.3%)
0.003
32 (6.8%)
64 (6.2%)
0.514
BARC bleeding
Type 3
8 (1.3%)
12 (1.0%)
0.498
7 (1.6%)
26 (2.6%)
0.085
Type 5
0 (0.0%)
3 (0.2%)
0.229
2 (0.4%)
3 (0.3%)
0.705
Stent thrombosis
Definite
8 (1.3%)
4 (0.3%)
0.015
1 (0.2%)
2 (0.2%)
0.942
Probable
2 (0.3%)
1 (0.1%)
0.223
0 (0%)
0 (0%)
NA
Definite or probable
10 (1.6%)
5 (0.4%)
0.006
1 (0.2%)
2 (0.2%)
0.942
Possible
2 (0.3%)
5 (0.4%)
0.814
15 (1.5%)
8 (1.6%)
0.974
Note. Incidences of events were calculated by the Kaplan–Meyer method. Cumulative incidences were compared with the log-rank test. ACS: acute coronary syndrome; SCAD: stable coronary artery disease; TLR: target lesion revascularization; BARC: bleeding academic research consortium.
